Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Liabilities: 2021-2025

Historic Other Non-Current Liabilities for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $14.5 million.

  • Kiniksa Pharmaceuticals International's Other Non-Current Liabilities rose 640.32% to $14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year increase of 640.32%. This contributed to the annual value of $1.8 million for FY2024, which is 1.88% down from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Other Non-Current Liabilities is $14.5 million, which was up 56.82% from $9.3 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Other Non-Current Liabilities' 5-year high stood at $14.5 million during Q3 2025, with a 5-year trough of $260,000 in Q2 2022.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Other Non-Current Liabilities had a median value of $1.9 million in 2024 and averaged $4.0 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Other Non-Current Liabilities crashed by 77.21% in 2022, and later surged by 640.32% in 2025.
  • Kiniksa Pharmaceuticals International's Other Non-Current Liabilities (Quarterly) stood at $270,000 in 2021, then soared by 581.11% to $1.8 million in 2022, then rose by 1.03% to $1.9 million in 2023, then decreased by 1.88% to $1.8 million in 2024, then skyrocketed by 640.32% to $14.5 million in 2025.
  • Its Other Non-Current Liabilities stands at $14.5 million for Q3 2025, versus $9.3 million for Q2 2025 and $5.1 million for Q1 2025.